Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.260
+0.100 (8.62%)
Jan 28, 2026, 2:16 PM EST - Market open
Ernexa Therapeutics Employees
Ernexa Therapeutics had 6 employees as of December 31, 2024. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
$167
Profits / Employee
-$3,059,500
Market Cap
9.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 6 | -2 | -25.00% |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | -1 | -10.00% |
| Dec 31, 2021 | 10 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 117 |
| Aptevo Therapeutics | 37 |
| SeaStar Medical Holding | 19 |
| BioVie | 13 |
| BioRestorative Therapies | 11 |
| XTL Biopharmaceuticals | 10 |
| MetaVia | 9 |
| TransCode Therapeutics | 7 |
ERNA News
- 1 day ago - Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program - GlobeNewsWire
- 22 days ago - Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D. - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics to Present at Oxford Global's Cell 2025 - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform - GlobeNewsWire